BioNano Genomics Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.77M), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $34.09. The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FNGU | |
|---|---|---|
Market Cap | $13.77M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.92 | $36.15 |
52-Week Low | $1.06 | $13.73 |
Enterprise Value | $16.38M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.
The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →